A monitoring checklist for brexpiprazole (brand name Rexulti) in Alzheimer's agitation covers lab tests, fall risk, mood and alertness changes, and warning signs that need a prescriber call. Brexpiprazole is the drug the FDA approved in May 2023 as the first medication specifically for agitation tied to Alzheimer's dementia, and its safety profile requires regular checking rather than a one-time prescription. Caregivers who track blood sugar, blood pressure, sleep patterns, and movement changes catch most problems before they become emergencies. This checklist organizes what to monitor, when, and why, based on the drug's FDA label and its Alzheimer's-specific trial data.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Before Starting — What Should Already Be Ruled Out
- Dosing — What the Schedule Should Look Like
- Lab Tests and Metabolic Monitoring
- Daily Signs Caregivers Can Track at Home
- Warning Signs That Need Immediate Medical Attention
- What the Evidence Does and Doesn't Cover
- Frequently Asked Questions
Before Starting — What Should Already Be Ruled Out
Brexpiprazole is not a first response to agitation. Prescribers and caregivers are expected to evaluate and treat reversible causes first — pain, infection, polypharmacy interactions, or acute delirium — and confirm the patient did not respond to non-drug approaches, according to Otsuka's dosing guide for agitation in Alzheimer's dementia.
This matters because agitation from an untreated urinary tract infection or an uncomfortable medication interaction looks identical to agitation from dementia itself, but responds to a completely different fix. A caregiver preparing for a prescriber visit can usefully ask whether pain, infection, constipation, and the patient's full medication list have already been checked.
- Pain or discomfort (dental, musculoskeletal, pressure sores)
- Infection, especially urinary tract infection
- Interactions among existing medications
- Acute delirium or a sudden change in environment
- Whether non-drug approaches (routine, redirection, environment changes) were tried first
Dosing — What the Schedule Should Look Like
Treatment starts low and increases slowly. The approved schedule begins at 0.5–1 mg once daily, titrates toward a 2 mg/day target, and may rise to a 3 mg/day maximum only after at least two weeks at 2 mg if the prescriber judges it necessary, according to Otsuka's dosing guide.
A 1 mg dose is not an approved long-term maintenance dose, and the drug is not meant to be given as needed for sudden episodes — it works as a steady daily treatment, not a rescue medication. A caregiver can watch for two dosing red flags: a prescription written for daily use at 1 mg with no plan to continue titrating, or any instruction to give it only when agitation flares up. Both depart from the approved schedule and are worth questioning directly with the prescriber.
Lab Tests and Metabolic Monitoring
Brexpiprazole carries the same metabolic risks as other atypical antipsychotics: elevated blood sugar, diabetes, abnormal cholesterol and triglycerides, and weight gain. The FDA prescribing information calls for a fasting glucose and lipid panel at or near the start of treatment, with periodic monitoring afterward. In longer-term use, patients gained an average of roughly 3.2 to 3.8 kg (about 7 to 8 pounds) by week 58, so a scale at home is a simple ongoing check between lab draws.
- Fasting glucose and lipid panel at treatment start
- Repeat panels on the schedule the prescriber sets
- Weight checks at home between visits
- Watch for new thirst, frequent urination, or unexplained fatigue — possible signs of rising blood sugar
Daily Signs Caregivers Can Track at Home
Several side effects showed up more often with brexpiprazole than with placebo in the Alzheimer's agitation trials: insomnia (4.7% versus 3.3%), a temporary worsening of agitation (3.5% versus 2.9%), and daytime sleepiness (3.3% versus 2.2%), based on trial data reported by Practical Neurology. These are common enough that a caregiver should expect to see at least one of them and know it is not automatically a reason to stop treatment, but it is worth reporting.
The label also warns of somnolence and postural hypotension — a drop in blood pressure when standing that can cause dizziness or falls. Because of this, the FDA prescribing information recommends a fall-risk assessment when treatment starts and periodically afterward, which matters most for physically frail Alzheimer's patients already unsteady on their feet.
- New or worsening insomnia
- Daytime drowsiness, especially if it affects walking or balance
- Dizziness or lightheadedness when standing up
- Any fall or near-fall since starting the medication
- A temporary spike in agitation rather than the expected improvement
Warning Signs That Need Immediate Medical Attention
Brexpiprazole keeps the boxed warning shared by its drug class: elderly patients with dementia-related psychosis treated with antipsychotics face an increased risk of death, a warning that applies even though brexpiprazole is approved only for agitation, not for psychosis on its own, per the FDA label. In the agitation trials themselves, overall mortality was low — 0.86% — and none of the deaths were judged treatment-related, according to trial results reported by Practical Neurology.
That context does not remove the warning; it describes what was observed in a controlled trial setting. The label separately warns of neuroleptic malignant syndrome (a rare but serious reaction involving high fever, muscle rigidity, and confusion), seizures, trouble regulating body temperature, and swallowing difficulty — all flagged in the FDA prescribing information. The temperature and swallowing warnings carry extra weight in Alzheimer's care, since many patients already struggle with heat tolerance or safe swallowing before medication is added.
- High fever combined with muscle stiffness or rigidity
- New confusion or sudden rigidity (possible neuroleptic malignant syndrome)
- Seizure activity
- Overheating or inability to cool down in warm environments
- New or worsening choking, coughing during meals, or trouble swallowing
What the Evidence Does and Doesn't Cover
The trials supporting this use were relatively short, about 12 weeks, and modest in size — roughly 700 patients combined across the two pivotal studies, according to trial data via Practical Neurology. Brexpiprazole has a longer safety track record in schizophrenia and depression, but that record comes from different, generally younger and less frail patient populations.
This means a caregiver monitoring a patient for months or years on the drug is operating with less long-term, Alzheimer's-specific safety data than the drug's overall history might suggest. Keeping the lab schedule, weight checks, and fall-risk conversations going at every follow-up visit is the practical way to fill that gap, since the available trials weren't long enough to show what happens over extended use in this specific population.
Frequently Asked Questions
Can brexpiprazole be given only when a patient becomes agitated, rather than daily?
No. The approved regimen is a steady once-daily dose that titrates upward over time; it is not approved for as-needed use, according to Otsuka's dosing guide.
Does the boxed warning about death risk apply even though the drug is approved for agitation, not psychosis?
Yes. The warning covers elderly dementia patients treated with antipsychotic drugs generally, and it remains on the label regardless of which symptom the drug is treating, per the FDA label.
How much weight gain is typical with longer-term use?
Trial data showed an average gain of about 3.2 to 3.8 kg (roughly 7 to 8 pounds) by week 58, according to the FDA prescribing information.
